No Data
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78
Gilead Sciences (GILD) has an average rating of outperform and price targets ranging from $67 to $119, according to analysts by Capital IQ.Price: 69.00, Change: +0.25, Percent Change: +0.36
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Hold Rating, Cuts Target Price to $74
Morgan Stanley analyst Terence Flynn maintains $Gilead Sciences(GILD.US)$ with a hold rating, and adjusts the target price from $78 to $74.According to TipRanks data, the analyst has a success rate
Pfizer Signals Progress on Obesity Pill, Boosting Stock
By Ciara Linnane and Eleanor Laise Oral versions of popular weight-loss drugs could be cheaper, more accessible, analysts say Pfizer Inc.'s stock (PFE) rose 2.8% early Thursday, after the drug
Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?
Supermengg :
103397071 : good
73958256 : translate
Paul bin Anthony : visit Singapore coming up
Paul bin Anthony : for young people with this learn about the best person in charge A1 Amen together